Open-label study with tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants with previously untreated, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with CEACAM5-positive tumors
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: SANOFI AVENTIS RECHERCHE & DEVELOPMENT
- Phase: II
- Execution start: 28/07/2021
- End of execution: 28/02/2023
- PI: JOAQUINA MARTINEZ GALAN